Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Youyi Fong, Yunda Huang, David Benkeser, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Principles and therapeutic applications of adaptive immunity
Hongbo Chi, Marion Pepper, Paul G. Thomas
Cell (2024) Vol. 187, Iss. 9, pp. 2052-2078
Open Access | Times Cited: 55
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
Nita Patel, Jessica F. Trost, Mimi Guebre‐Xabier, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study
Katia Alves, Karen L. Kotloff, R. Scott McClelland, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 1
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
Germán Áñez, Lisa M. Dunkle, Cynthia L. Gay, et al.
JAMA Network Open (2023) Vol. 6, Iss. 4, pp. e239135-e239135
Open Access | Times Cited: 38
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 35
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
David Benkeser, David C. Montefiori, Adrian B. McDermott, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 692
Open Access | Times Cited: 33
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
David Benkeser, Youyi Fong, Holly Janes, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 26
SARS-CoV-2 correlates of protection from infection against variants of concern
Kaiyuan Sun, Jinal N. Bhiman, Stefano Tempia, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 2805-2812
Closed Access | Times Cited: 8
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Chijioke Bennett, Wayne Woo, Mark Bloch, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 6, pp. 581-593
Open Access | Times Cited: 7
Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning
Katharina Röltgen, Scott D. Boyd
Annual Review of Pathology Mechanisms of Disease (2023) Vol. 19, Iss. 1, pp. 69-97
Open Access | Times Cited: 15
Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial
Peter B. Gilbert, Youyi Fong, Nima S. Hejazi, et al.
Vaccine (2024) Vol. 42, Iss. 9, pp. 2181-2190
Closed Access | Times Cited: 6
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Alexander A. Cohen, Jennifer R. Keeffe, Ariën Schiepers, et al.
Cell (2024) Vol. 187, Iss. 20, pp. 5554-5571.e19
Open Access | Times Cited: 6
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Alexander A. Cohen, Jennifer R. Keeffe, Ariën Schiepers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 5
A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection
Jun Liu, Li Wang, Alexandra Kurtesi, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Bo Zhang, Youyi Fong, Lauren Dang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections
José Víctor Zambrana, Ian A. Mellis, Abigail Shotwell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies
Lucia Spicuzza, Davide Campagna, Chiara Di Maria, et al.
AIMS Microbiology (2023) Vol. 9, Iss. 2, pp. 375-401
Open Access | Times Cited: 14
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients
Muneerah M Aleissa, Jessica S Little, Sonya Davey, et al.
Transplantation and Cellular Therapy (2023) Vol. 29, Iss. 6, pp. 398.e1-398.e5
Open Access | Times Cited: 13
Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time
Grace Kenny, Sophie O’Reilly, N. Kelly, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 13
A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation
Zhaohui Cai, Raj Kalkeri, Mingzhu Zhu, et al.
Microorganisms (2024) Vol. 12, Iss. 3, pp. 501-501
Open Access | Times Cited: 4
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
Ying Huang, Nima S. Hejazi, Bryan S. Blette, et al.
Viruses (2023) Vol. 15, Iss. 10, pp. 2029-2029
Open Access | Times Cited: 11
Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection
Kimia Sobhani, Susan Cheng, Raquel A. Binder, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1644-1644
Open Access | Times Cited: 11
Plant stanol consumption increases anti-COVID-19 antibody responses, independent of changes in serum cholesterol concentrations: a randomized controlled trial
Lieve van Brakel, Ronald P. Mensink, Dieter Lütjohann, et al.
American Journal of Clinical Nutrition (2024) Vol. 119, Iss. 4, pp. 969-980
Open Access | Times Cited: 3
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial
Kenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, et al.
Vaccine (2024) Vol. 42, Iss. 6, pp. 1319-1325
Open Access | Times Cited: 3
Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study
Mangaiarkarasi Asokan, Roshni Florina Joan, Sudhir Babji, et al.
The Lancet Regional Health - Southeast Asia (2024) Vol. 22, pp. 100361-100361
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top